| Clinical pharmacokinetics and pharmacodynamics of immune checkpoint inhibitors M Centanni, DJAR Moes, IF Trocóniz, J Ciccolini, JGC van Hasselt Clinical pharmacokinetics 58, 835-857, 2019 | 279 | 2019 |
| Propranolol potentiates the anti-angiogenic effects and anti-tumor efficacy of chemotherapy agents: implication in breast cancer treatment E Pasquier, J Ciccolini, M Carre, S Giacometti, R Fanciullino, C Pouchy, ... Oncotarget 2 (10), 797, 2011 | 259 | 2011 |
| Computational oncology—mathematical modelling of drug regimens for precision medicine D Barbolosi, J Ciccolini, B Lacarelle, F Barlési, N André Nature reviews Clinical oncology 13 (4), 242-254, 2016 | 224 | 2016 |
| Pharmacokinetics and pharmacogenetics of Gemcitabine as a mainstay in adult and pediatric oncology: an EORTC-PAMM perspective J Ciccolini, C Serdjebi, GJ Peters, E Giovannetti Cancer chemotherapy and pharmacology 78, 1-12, 2016 | 194 | 2016 |
| Mathematical modeling of cancer immunotherapy and its synergy with radiotherapy R Serre, S Benzekry, L Padovani, C Meille, N André, J Ciccolini, F Barlesi, ... Cancer research 76 (17), 4931-4940, 2016 | 173 | 2016 |
| Pharmacogenetics of capecitabine in advanced breast cancer patients R Largillier, MC Etienne-Grimaldi, JL Formento, J Ciccolini, JF Nebbia, ... Clinical cancer research 12 (18), 5496-5502, 2006 | 148 | 2006 |
| Cytidine deaminase residual activity in serum is a predictive marker of early severe toxicities in adults after gemcitabine-based chemotherapies J Ciccolini, L Dahan, N André, A Evrard, M Duluc, A Blesius, C Yang, ... Journal of clinical oncology 28 (1), 160-165, 2010 | 145 | 2010 |
| Increased cytotoxicity and bystander effect of 5-fluorouracil and 5′-deoxy-5-fluorouridine in human colorectal cancer cells transfected with thymidine phosphorylase A Evrard, P Cuq, J Ciccolini, L Vian, JP Cano British journal of cancer 80 (11), 1726-1733, 1999 | 138 | 1999 |
| Mathematical modeling of tumor growth and metastatic spreading: validation in tumor-bearing mice N Hartung, S Mollard, D Barbolosi, A Benabdallah, G Chapuisat, G Henry, ... Cancer research 74 (22), 6397-6407, 2014 | 126 | 2014 |
| Population modeling of tumor growth curves and the reduced Gompertz model improve prediction of the age of experimental tumors C Vaghi, A Rodallec, R Fanciullino, J Ciccolini, JP Mochel, M Mastri, ... PLoS computational biology 16 (2), e1007178, 2020 | 122 | 2020 |
| Optimization of trans-Resveratrol bioavailability for human therapy MJ Amiot, B Romier, TMA Dao, R Fanciullino, J Ciccolini, R Burcelin, ... Biochimie 95 (6), 1233-1238, 2013 | 122 | 2013 |
| Optimizing druggability through liposomal formulations: new approaches to an old concept D Bitounis, R Fanciullino, A Iliadis, J Ciccolini International Scholarly Research Notices 2012 (1), 738432, 2012 | 121 | 2012 |
| Challenges, expectations and limits for nanoparticles-based therapeutics in cancer: a focus on nano-albumin-bound drugs R Fanciullino, J Ciccolini, G Milano Critical reviews in oncology/hematology 88 (3), 504-513, 2013 | 120 | 2013 |
| A rapid and inexpensive method for anticipating severe toxicity to fluorouracil and fluorouracil-based chemotherapy J Ciccolini, C Mercier, A Evrard, L Dahan, JC Boyer, F Duffaud, K Richard, ... Therapeutic drug monitoring 28 (5), 678-685, 2006 | 119 | 2006 |
| Routine dihydropyrimidine dehydrogenase testing for anticipating 5-fluorouracil–related severe toxicities: hype or hope? J Ciccolini, E Gross, L Dahan, B Lacarelle, C Mercier Clinical colorectal cancer 9 (4), 224-228, 2010 | 118 | 2010 |
| Liposome-encapsulated anticancer drugs: still waiting for the magic bullet? R Fanciullino, J Ciccolini Current medicinal chemistry 16 (33), 4361-4373, 2009 | 114 | 2009 |
| A simple and rapid high‐performance liquid chromatographic (HPLC) method for 5‐fluorouracil (5‐FU) assay in plasma and possible detection of patients with impaired … J Ciccolini, C Mercier, MF Blachon, R Favre, A Durand, B Lacarelle Journal of clinical pharmacy and therapeutics 29 (4), 307-315, 2004 | 108 | 2004 |
| Antiproliferative effect of ascorbic acid is associated with the inhibition of genes necessary to cell cycle progression S Belin, F Kaya, G Duisit, S Giacometti, J Ciccolini, M Fontés PloS one 4 (2), e4409, 2009 | 101 | 2009 |
| DPD-based adaptive dosing of 5-FU in patients with head and neck cancer: impact on treatment efficacy and toxicity CG Yang, J Ciccolini, A Blesius, L Dahan, D Bagarry-Liegey, C Brunet, ... Cancer chemotherapy and pharmacology 67, 49-56, 2011 | 100 | 2011 |
| Molecular mechanisms underlying the interaction between ZD1839 (‘Iressa’) and cisplatin/5-fluorouracil N Magne, JL Fischel, C Tiffon, P Formento, A Dubreuil, N Renee, ... British journal of cancer 89 (3), 585-592, 2003 | 96 | 2003 |
